carboplatin + paclitaxel + vandetanib

This is an investigational combination therapy consisting of three agents: carboplatin, paclitaxel, and vandetanib. Carboplatin is an alkylating platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis in rapidly dividing cells. Paclitaxel is a microtubule-stabilizing chemotherapeutic that inhibits cell division by preventing microtubule depolymerization. Vandetanib is an oral small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2), epidermal growth factor receptor (EGFR), and RET proto-oncogene, thereby inhibiting tumor angiogenesis and proliferation. The triple regimen has been studied in phase II clinical trials for non-small-cell lung cancer and in early-phase studies for esophageal cancer[1][2][6]. The rationale behind this combination is to enhance antitumor efficacy by combining cytotoxic chemotherapy with targeted inhibition of key signaling pathways involved in tumor growth and angiogenesis.

Other names

VPC regimenvandetanib/paclitaxel/carboplatin